Science Creates

Alumn

Active

Status

2017

Founded

Development stage

No items found.

FluoretiQ is developing diagnostic tools to significantly improve the speed, accuracy and quality of information available to clinicians and veterinarians at the point of care. Its proprietary technology platform rapidly identifies and quantifies bacteria in 15 minutes via an advanced latex agglutination test. Its second platform is a real-time antibiotic susceptibility test that determines the most effective antibiotic to prescribe within 30 minutes. They are designed to save time, antibiotics and, most importantly, lives.

Founding team

Key contacts

Neciah Dorh

CEO

Neciah leads FluoretiQ’s vision and since co-founding the company has attracted grant and investment funding opportunities, and forged long-term strategic partnerships to ensure patients receive the most effective antibiotic first time. Prior to this, Neciah studied at the University of Bristol, earning a PhD, Research Postdoctorate and Enterprise Fellowship in Quantum Technology.

Josephine Dorh

CTO

As co-inventor of FluoretiQ’s NANOPLEX™ technology, Josephine leads the company’s multi-disciplinary R&D team in developing a fast and accurate diagnostic platform. This follows on from the expertise Josephine gained during her time as a Research Collaborator and Visiting Industrial Fellow at the University of Bristol, where her focus was photonic device design.

Back to directory